PTJ
IMVT icon

Paul Tudor Jones’s Immunovant IMVT Stock Holding History

Paul Tudor Jones’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,100
Closed -$587K – 3945
2025
Q4 		$587K Buy
+23,100
New +$515K ﹤0.01% 2621

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paul Tudor Jones's IMVT Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Immunovant (IMVT) in Q2 2026: 57,145 shares worth $2.2M. The stake represents ﹤0.01% of the portfolio and ranks #1879 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in IMVT as recently as Q4 2025.

Paul Tudor Jones first reported a position in IMVT in Q1 2023 and has held it in 7 quarters since. The position peaked at $2.82M in Q1 2024. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Paul Tudor Jones held 57,145 shares of Immunovant worth $2.2M as of Q2 2026.
  • Immunovant was a new Paul Tudor Jones position in Q2 2026.
  • Immunovant made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1879 holding.
  • Paul Tudor Jones first reported a position in Immunovant in Q1 2023 and has held it in 7 quarters since.
  • Paul Tudor Jones's Immunovant position peaked at $2.82M in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.